Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAXIMISE secukinumab trial in axial psoriatic arthritis
2016-000814-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) and psoriatic spondylitis (3 arms), sponsored by Novartis. Primary endpoint: Assessment of SpondyloArthritis International Society 20 response. Started Jun 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)psoriatic spondylitis
Beyond the preview
Go deeper on 2016-000814-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000814-31.